Plain-English translation of NCT05552157 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This study is testing an investigational medication called Remternetug to see if it can prevent or delay cognitive decline in people who carry specific genetic mutations known to cause early-onset Alzheimer's disease. You would be enrolled before you develop any symptoms of memory loss or thinking problems. The medication has been designed to target the biological changes that lead to Alzheimer's disease in these inherited forms.
Families with these genetic mutations have an extremely high chance of developing Alzheimer's disease at a predictable age. This trial exists because identifying people at-risk years before symptoms appear offers a unique opportunity to test whether treating them early—before brain damage becomes severe—can prevent or delay the disease entirely.
You likely qualify if…
You likely don't qualify if…
You would visit the study center multiple times over several months for clinical assessments, memory and thinking tests, brain imaging (MRI scans), and blood or spinal fluid samples. You would be randomly assigned to receive either the medication or a placebo (inactive pill) in a blinded fashion, meaning neither you nor the researchers will know which you're receiving. After the first stage, participants may have the option to continue with the open-label medication in stage two.
AI-generated summary from trial data · Jun 7, 2026 · Not medical advice
United States